Literature DB >> 9701268

Enzyme-linked immunosorbent assay spot detection of interferon-gamma and interleukin 5-producing cells as a predictive marker for renal allograft failure.

M Tary-Lehmann1, D E Hricik, A C Justice, N S Potter, P S Heeger.   

Abstract

BACKGROUND: Despite improvements in the short-term survival of renal transplants, many allografts fail over the 5-10 years after transplantation. We sought to identify an immunologic assay that could identify those patients at high risk for future allograft failure.
METHODS: Blood samples were obtained from 23 renal allograft recipients with acute and/or chronic graft dysfunction and from 22 controls. Isolated peripheral blood lymphocytes (PBLs) were tested for interferon (IFN)-gamma and interleukin (IL)-5 production using an enzyme-linked immunosorbent spot assay. IFN-gamma:IL-5 ratios were calculated and compared between groups. Among the 23 patients with graft dysfunction, the ratios were also compared with graft function at 6 months.
RESULTS: IFN-gamma:IL-5 ratios of > or = 15 were associated with allograft rejection episodes in 8 of 12 cases, whereas 10 of 11 episodes of graft dysfunction from other causes (infection, drug toxicity, obstruction) were associated with values <15. All normal controls had values <15 (22/22). Among the graft recipients with acute renal failure, all patients with IFN-gamma:IL-5 ratios <15 exhibited improved renal function at 6-month follow-up (14/14), whereas 8 of 9 patients with IFN-gamma:IL-5 ratios > or = 15 developed allograft failure at 6 months (sensitivity 100%, specificity 93.3%).
CONCLUSION: In renal transplant recipients with acute allograft dysfunction, mitogen-induced peripheral blood lymphocyte IFN-gamma:IL-5 ratios > or = 15 were highly predictive of allograft failure within 6 months of the assay. This test may be a useful prognostic marker for identification of transplant recipients with acute graft dysfunction who are at high risk for future graft loss and thus allow targeted therapeutic interventions to prolong graft survival.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9701268     DOI: 10.1097/00007890-199807270-00014

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  12 in total

Review 1.  Detecting adaptive immunity: applications in transplantation monitoring.

Authors:  Georg A Böhmig; Markus Wahrmann; Marcus D Säemann
Journal:  Mol Diagn Ther       Date:  2010-02-01       Impact factor: 4.074

2.  The direct and indirect allogeneic presentation pathway during acute rejection after human cardiac transplantation.

Authors:  N M van Besouw; J M Zuijderwijk; L M B Vaessen; A H M M Balk; A P W M Maat; P H van der Meide; W Weimar
Journal:  Clin Exp Immunol       Date:  2005-09       Impact factor: 4.330

3.  Telomerase-based pharmacologic enhancement of antiviral function of human CD8+ T lymphocytes.

Authors:  Steven Russell Fauce; Beth D Jamieson; Allison C Chin; Ronald T Mitsuyasu; Stan T Parish; Hwee L Ng; Christina M Ramirez Kitchen; Otto O Yang; Calvin B Harley; Rita B Effros
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

4.  Standardization and cross validation of alloreactive IFNγ ELISPOT assays within the clinical trials in organ transplantation consortium.

Authors:  I Ashoor; N Najafian; Y Korin; E F Reed; T Mohanakumar; D Ikle; P S Heeger; M Lin
Journal:  Am J Transplant       Date:  2013-05-24       Impact factor: 8.086

5.  T-cell immune monitoring in organ transplantation.

Authors:  Rajani Dinavahi; Peter S Heeger
Journal:  Transplantation       Date:  2009-11-27       Impact factor: 4.939

6.  Codominant Role of Interferon-γ- and Interleukin-17-Producing T Cells During Rejection in Full Facial Transplant Recipients.

Authors:  T J Borges; J T O'Malley; L Wo; N Murakami; B Smith; J Azzi; S Tripathi; J D Lane; E M Bueno; R A Clark; S G Tullius; A Chandraker; C G Lian; G F Murphy; T B Strom; B Pomahac; N Najafian; L V Riella
Journal:  Am J Transplant       Date:  2016-04-07       Impact factor: 8.086

7.  A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin.

Authors:  D G Alleva; P D Crowe; L Jin; W W Kwok; N Ling; M Gottschalk; P J Conlon; P A Gottlieb; A L Putnam; A Gaur
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

8.  Interferon Gamma ELISPOT Testing as a Risk-Stratifying Biomarker for Kidney Transplant Injury: Results From the CTOT-01 Multicenter Study.

Authors:  D E Hricik; J Augustine; P Nickerson; R N Formica; E D Poggio; D Rush; K A Newell; J Goebel; I W Gibson; R L Fairchild; K Spain; D Iklé; N D Bridges; P S Heeger
Journal:  Am J Transplant       Date:  2015-07-30       Impact factor: 8.086

9.  Effects of cellular sensitization and donor age on acute rejection and graft function after deceased-donor kidney transplantation.

Authors:  Donald E Hricik; Emilio D Poggio; Kenneth J Woodside; Naragaju Sarabu; Edmund Q Sanchez; James A Schulak; Aparna Padiyar; Peter S Heeger; Joshua J Augustine
Journal:  Transplantation       Date:  2013-05-27       Impact factor: 4.939

Review 10.  T-cell immune monitoring in organ transplantation.

Authors:  Rajani Dinavahi; Peter S Heeger
Journal:  Curr Opin Organ Transplant       Date:  2008-08       Impact factor: 2.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.